Global Cancer Gene Therapy Market : Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012 to 2016 and Forecast 2017 to 2023

November 2017 | 209 pages | ID: GD306353419EN
Precision Business Insights (PBI)

Abstracts

Cancer Gene Therapy Market

Cancer gene therapy is a process that treats cancers by inserting therapeutic DNA into the patient. Cancer gene therapy is gaining popularity as a result of its success rate in preclinical and clinical trial stages. The most common technique for cancer gene therapy involves replacing a mutated gene that is causing cancer with a healthy copy of the gene. A new technique that is being introduced to cancer gene therapy market involves insertion of new genes into the body that would help to fight against tumor cells.

Globally, rising cancer prevalence will increase demand for gene therapy as the effective personalized treatment choice. Various factors, such as the increase in the prevalence of cancer, rising government initiatives, increase in funding from various government and non-government organizations, ethical acceptance of gene therapy for treatment of diseases and growing popularity of DNA vaccines is driving the global cancer gene therapy market. However, less awareness and high cost involved in treatment, Lack of reimbursement policies for advanced gene therapy methods are restraining the growth of the global market for cancer gene therapy.

The Global cancer gene therapy market is segmented on the basis of type, therapy, end-user and regional

Based on the type, global cancer gene therapy market is segmented as:

• Gene Induced Immunotherapy
• Tumour Antigen Gene Delivery
• Cytokine Gene Delivery
• Oncolytic Virotherapy
• Adenoviruses
• Adeno Associated Virus
• Lentiviruses
• Alpha Virus
• Retrovirus
• Herpes Simplex Virus
• Vaccinia virus
• Simian Virus
• Gene Transfer/Gene Replacement
• Electroporation
• Magnetofection
• Naked/Plasmid Vectors
• Gene Gun
• Sonoporation

Based on the therapy, global cancer gene therapy market is segmented as:

• Retroviral Therapy
• Adenoviral Therapy

Based on the end-user, global cancer gene therapy market is segmented as:

• Hospitals
• Oncology institutes
• Biotechnological companies
• Clinical Research Labs

Global cancer gene therapy market is highly fragmented with small biotech firms holding a chunk of the overall industry share. Major industry participants adopting various strategies to retaining their market positions such as the development of advanced technologies, maintaining a strong intellectual property, strategic collaborations, and joint ventures adopted by in the global cancer gene therapy. As per WHO, cancer incidence is projected to rise by 50% to reach 15 Mn by the end of this decade. This alarming increase in the number of patients and side effects associated with various chemotherapy drugs necessitates this as a potential treatment approach addressing the growing global burden of the cancers. Small biotech firms dominate the global cancer gene therapy market than the bigger players. The players are constantly engaged in R&D in order to develop novel methods to treat various life-threatening diseases. Increased in the adoption of emerging genomic technologies such as Next Generation Sequencing (NGS) and high-density microarray coupled with favorable government initiatives will fuel global cancer gene therapy market. For instance, CDC supports nationwide screening programs for control of breast, cervical and colorectal cancer among low-income women with little or no health insurance.

Geographically, the cancer gene therapy is segmented into North America, Europe, Latin America, Asia- Pacific and the Middle East and Africa. North America leads the global cancer gene therapy market owing to the large pool of aging population and advancements in technology high investments in R & D activities along with the government support will boost industry demand. The U.K. market is anticipated to grow rapidly over the forecast period due to the rising occurrence of cancer along with the increase in acceptance of gene technology. Asia-Pacific is expected to witness high growth in cancer gene therapy market, due to increase in government initiatives, rising economy, and improvement in healthcare infrastructure in the region. Some of the key driving forces for cancer gene therapy market in emerging countries are increasing R&D investment, a large pool of patients and rising government funding.

Some of the major companies operating in the global cancer gene therapy market are Urigen Pharmaceuticals Inc. (U.S), GenVec.Inc (U.S), Oxford BioMedica (U.K), Vical (U.S), ANI Pharmaceuticals, Inc. (U.S), and Genzyme Corporation (U.S). Novartis AG (Switzerland), and Cell Medica (U.K.)

In July 2017, Novartis received U.S. FDA Oncologic Drugs Advisory Committee (ODAC) recommended approval of CTL019, an investigational chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of relapsed or refractory pediatric and young adult patients with B-cell acute lymphoblastic leukemia.

In June 2017, Cell Medica acquired the Catapult Therapy TCR Limited, a subsidiary of Cell and Gene Therapy Catapult (CGT Catapult), and the initiation of a collaboration to establish cell therapy manufacturing for Cell Medica at CGT Catapult’s GMP manufacturing facility in Stevenage, UK.

In June 2013, BioSante Pharmaceuticals, Inc. completed the merger of its wholly-owned subsidiary with and into ANIP Acquisition Company, ANI Pharmaceuticals, Inc.

Report Outline:

• The report provides granular level information about the market size, regional market share, and forecast from 2017-2023
• The report covers in-detail insights about the competitor’s overview, key findings, and their key strategies
• The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
• The report tracks recent innovations, key developments and startup’s details that are working in the industry
• The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario

Contents

1. EXECUTIVE SUMMARY

2. GLOBAL CANCER GENE THERAPY MARKET INTRODUCTION

2.1. Global Cancer Gene Therapy Market – Taxonomy
2.2. Global Cancer Gene Therapy Market –Definitions
  2.2.1. Type
  2.2.2. Therapy
  2.2.3. End User

3. GLOBAL CANCER GENE THERAPY MARKET DYNAMICS

3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Cancer Gene Therapy Market Dynamics – Factors Impact Analysis
3.6. Global Cancer Gene Therapy Market – Regulations
  3.6.1. U.S
  3.6.2. Europe
  3.6.3. Japan
  3.6.4. China
3.7. Global Cancer Gene Therapy Market – Product Innovations

4. GLOBAL CANCER GENE THERAPY MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023

4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis

5. GLOBAL CANCER GENE THERAPY MARKET, BY TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023

5.1. Gene Induced Immunotherapy
  5.1.1. Tumour Antigen Gene Delivery
    5.1.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
    5.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
    5.1.1.3. Market Opportunity Analysis
  5.1.2. Cytokine Gene Delivery
    5.1.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
    5.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
    5.1.2.3. Market Opportunity Analysis
5.2. Oncolytic Virotherapy
  5.2.1. Adenoviruses
    5.2.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
    5.2.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
    5.2.1.3. Market Opportunity Analysis
  5.2.2. Adeno Associated Virus
    5.2.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
    5.2.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
    5.2.2.3. Market Opportunity Analysis
  5.2.3. Lentiviruses
    5.2.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
    5.2.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
    5.2.3.3. Market Opportunity Analysis
  5.2.4. Alpha Virus
    5.2.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
    5.2.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
    5.2.4.3. Market Opportunity Analysis
  5.2.5. Retrovirus
    5.2.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
    5.2.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
    5.2.5.3. Market Opportunity Analysis
  5.2.6. Herpes Simplex Virus
    5.2.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
    5.2.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
    5.2.6.3. Market Opportunity Analysis
  5.2.7. Vaccinia virus
    5.2.7.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
    5.2.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
    5.2.7.3. Market Opportunity Analysis
  5.2.8. Simian Virus
    5.2.8.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
    5.2.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
    5.2.8.3. Market Opportunity Analysis
5.3. Gene Transfer/Gene Replacement
  5.3.1. Electroporation
    5.3.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
    5.3.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
    5.3.1.3. Market Opportunity Analysis
  5.3.2. Magnetofection
    5.3.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
    5.3.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
    5.3.2.3. Market Opportunity Analysis
  5.3.3. Naked / Plasmid Vectors
    5.3.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
    5.3.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
    5.3.3.3. Market Opportunity Analysis
  5.3.4. Gene Gun
    5.3.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
    5.3.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
    5.3.4.3. Market Opportunity Analysis
  5.3.5. Sonoporation
    5.3.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
    5.3.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
    5.3.5.3. Market Opportunity Analysis

6. GLOBAL CANCER GENE THERAPY MARKET FORECAST, BY THERAPY, 2012 - 2016 AND FORECAST, 2017 - 2023

6.1. Retroviral Therapy
  6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  6.1.3. Market Opportunity Analysis
6.2. Adenoviral Therapy
  6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  6.2.3. Market Opportunity Analysis

7. GLOBAL CANCER GENE THERAPY MARKET FORECAST, BY END USER, 2012 - 2016 AND FORECAST, 2017 - 2023

7.1. Hospitals
  7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  7.1.3. Market Opportunity Analysis
7.2. Oncology institutes
  7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  7.2.3. Market Opportunity Analysis
7.3. Biotechnological companies
  7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  7.3.3. Market Opportunity Analysis
7.4. Clinical Research Labs
  7.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  7.4.3. Market Opportunity Analysis

8. GLOBAL CANCER GENE THERAPY MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023

8.1. North America
  8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  8.1.3. Market Opportunity Analysis
8.2. Europe
  8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
  8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  8.3.3. Market Opportunity Analysis
8.4. Latin America
  8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
  8.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  8.5.3. Market Opportunity Analysis
8.6. Global Cancer Gene Therapy Market - Opportunity Analysis Index, By Type, Therapy, End User, and Region, 2017 – 2023

9. NORTH AMERICA CANCER GENE THERAPY MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  9.1.1. Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    9.1.1.1. Gene Induced Immunotherapy
      9.1.1.1.1. Tumour Antigen Gene Delivery
      9.1.1.1.2. Cytokine Gene Delivery
    9.1.1.2. Oncolytic Virotherapy
      9.1.1.2.1. Adenoviruses
      9.1.1.2.2. Adeno Associated Virus
      9.1.1.2.3. Lentiviruses
      9.1.1.2.4. Alpha Virus
      9.1.1.2.5. Retrovirus
      9.1.1.2.6. Herpes Simplex Virus
      9.1.1.2.7. Vaccinia virus
      9.1.1.2.8. Simian Virus
    9.1.1.3. Gene Transfer/ Gene Replacement
      9.1.1.3.1. Electroporation
      9.1.1.3.2. Magnetofection
      9.1.1.3.3. Naked / Plasmid Vectors
      9.1.1.3.4. Gene Gun
      9.1.1.3.5. Sonoporation
  9.1.2. Therapy Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      9.1.2.1.1. Retroviral Therapy
      9.1.2.1.2. Adenoviral Therapy
  9.1.3. End User Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    9.1.3.1. Hospitals
    9.1.3.2. Oncology institutes
    9.1.3.3. Biotechnological companies
    9.1.3.4. Clinical Research Labs
  9.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
    9.1.4.1. U.S.
    9.1.4.2. Canada
  9.1.5. North America Cancer Gene Therapy Market - Opportunity Analysis Index, By Type, Therapy, End User and Country, 2017 – 2023
  9.1.6. North America Cancer Gene Therapy Market Dynamics – Trends

10. EUROPE CANCER GENE THERAPY MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  10.1.1. Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    10.1.1.1. Gene Induced Immunotherapy
      10.1.1.1.1. Tumour Antigen Gene Delivery
      10.1.1.1.2. Cytokine Gene Delivery
    10.1.1.2. Oncolytic Virotherapy
      10.1.1.2.1. Adenoviruses
      10.1.1.2.2. Adeno Associated Virus
      10.1.1.2.3. Lentiviruses
      10.1.1.2.4. Alpha Virus
      10.1.1.2.5. Retrovirus
      10.1.1.2.6. Herpes Simplex Virus
      10.1.1.2.7. Vaccinia virus
      10.1.1.2.8. Simian Virus
    10.1.1.3. Gene Transfer/ Gene Replacement
      10.1.1.3.1. Electroporation
      10.1.1.3.2. Magnetofection
      10.1.1.3.3. Naked / Plasmid Vectors
      10.1.1.3.4. Gene Gun
      10.1.1.3.5. Sonoporation
  10.1.2. Therapy Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      10.1.2.1.1. Retroviral Therapy
      10.1.2.1.2. Adenoviral Therapy
  10.1.3. End User Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.3.1. Hospitals
    10.1.3.2. Oncology institutes
    10.1.3.3. Biotechnological companies
    10.1.3.4. Clinical Research Labs
  10.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.4.1. Germany
    10.1.4.2. UK
    10.1.4.3. France
    10.1.4.4. Spain
    10.1.4.5. Italy
    10.1.4.6. Russia
    10.1.4.7. Poland
    10.1.4.8. Rest of Europe
  10.1.5. Europe Cancer Gene Therapy Market - Opportunity Analysis Index, By Type, Therapy, End User and Country, 2017 – 2023
  10.1.6. Europe Cancer Gene Therapy Market Dynamics – Trends

11. ASIA-PACIFIC CANCER GENE THERAPY MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  11.1.1. Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    11.1.1.1. Gene Induced Immunotherapy
      11.1.1.1.1. Tumour Antigen Gene Delivery
      11.1.1.1.2. Cytokine Gene Delivery
    11.1.1.2. Oncolytic Virotherapy
      11.1.1.2.1. Adenoviruses
      11.1.1.2.2. Adeno Associated Virus
      11.1.1.2.3. Lentiviruses
      11.1.1.2.4. Alpha Virus
      11.1.1.2.5. Retrovirus
      11.1.1.2.6. Herpes Simplex Virus
      11.1.1.2.7. Vaccinia virus
      11.1.1.2.8. Simian Virus
    11.1.1.3. Gene Transfer/ Gene Replacement
      11.1.1.3.1. Electroporation
      11.1.1.3.2. Magnetofection
      11.1.1.3.3. Naked / Plasmid Vectors
      11.1.1.3.4. Gene Gun
      11.1.1.3.5. Sonoporation
  11.1.2. Therapy Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      11.1.2.1.1. Retroviral Therapy
      11.1.2.1.2. Adenoviral Therapy
  11.1.3. End User Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.3.1. Hospitals
    11.1.3.2. Oncology institutes
    11.1.3.3. Biotechnological companies
    11.1.3.4. Clinical Research Labs
  11.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
    11.1.4.1. Japan
    11.1.4.2. China
    11.1.4.3. India
    11.1.4.4. ASEAN
    11.1.4.5. Australia & New Zealand
    11.1.4.6. Rest of Asia-Pacific
  11.1.5. Asia-Pacific Cancer Gene Therapy Market - Opportunity Analysis Index, By Type, Therapy, End User r and Country, 2017 – 2023
  11.1.6. Europe Cancer Gene Therapy Market Dynamics – Trends

12. LATIN AMERICA CANCER GENE THERAPY MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  12.1.1. Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    12.1.1.1. Gene Induced Immunotherapy
      12.1.1.1.1. Tumour Antigen Gene Delivery
      12.1.1.1.2. Cytokine Gene Delivery
    12.1.1.2. Oncolytic Virotherapy
      12.1.1.2.1. Adenoviruses
      12.1.1.2.2. Adeno Associated Virus
      12.1.1.2.3. Lentiviruses
      12.1.1.2.4. Alpha Virus
      12.1.1.2.5. Retrovirus
      12.1.1.2.6. Herpes Simplex Virus
      12.1.1.2.7. Vaccinia virus
      12.1.1.2.8. Simian Virus
    12.1.1.3. Gene Transfer/ Gene Replacement
      12.1.1.3.1. Electroporation
      12.1.1.3.2. Magnetofection
      12.1.1.3.3. Naked / Plasmid Vectors
      12.1.1.3.4. Gene Gun
      12.1.1.3.5. Sonoporation
  12.1.2. Therapy Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      12.1.2.1.1. Retroviral Therapy
      12.1.2.1.2. Adenoviral Therapy
  12.1.3. End User Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.3.1. Hospitals
    12.1.3.2. Oncology institutes
    12.1.3.3. Biotechnological companies
    12.1.3.4. Clinical Research Labs
  12.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.4.1. Brazil
    12.1.4.2. Mexico
    12.1.4.3. Argentina
    12.1.4.4. Venezuela
    12.1.4.5. Rest of Latin America
  12.1.5. Latin America Cancer Gene Therapy Market - Opportunity Analysis Index, By Type, Therapy, End User and Country, 2017 – 2023
  12.1.6. Latin America Cancer Gene Therapy Market Dynamics – Trends

13. MIDDLE EAST AND AFRICA CANCER GENE THERAPY MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  13.1.1. Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    13.1.1.1. Gene Induced Immunotherapy
      13.1.1.1.1. Tumour Antigen Gene Delivery
      13.1.1.1.2. Cytokine Gene Delivery
    13.1.1.2. Oncolytic Virotherapy
      13.1.1.2.1. Adenoviruses
      13.1.1.2.2. Adeno Associated Virus
      13.1.1.2.3. Lentiviruses
      13.1.1.2.4. Alpha Virus
      13.1.1.2.5. Retrovirus
      13.1.1.2.6. Herpes Simplex Virus
      13.1.1.2.7. Vaccinia virus
      13.1.1.2.8. Simian Virus
    13.1.1.3. Gene Transfer/ Gene Replacement
      13.1.1.3.1. Electroporation
      13.1.1.3.2. Magnetofection
      13.1.1.3.3. Naked / Plasmid Vectors
      13.1.1.3.4. Gene Gun
      13.1.1.3.5. Sonoporation
  13.1.2. Therapy Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      13.1.2.1.1. Retroviral Therapy
      13.1.2.1.2. Adenoviral Therapy
  13.1.3. End User Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    13.1.3.1. Hospitals
    13.1.3.2. Oncology institutes
    13.1.3.3. Biotechnological companies
    13.1.3.4. Clinical Research Labs
  13.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    13.1.4.1. Gulf Cooperation Council (GCC) Countries
    13.1.4.2. Israel
    13.1.4.3. South Africa
    13.1.4.4. Rest of MEA
  13.1.5. MEA Cancer Gene Therapy Market - Opportunity Analysis Index, By Type, Therapy, End User and Country, 2017 – 2023
  13.1.6. MEA Cancer Gene Therapy Market Dynamics – Trends

14. COMPETITION LANDSCAPE

14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
  14.2.1. Urigen Pharmaceuticals Inc. (U.S)
  14.2.2. GenVec.Inc (U.S)
  14.2.3. Oxford BioMedica (UK)
  14.2.4. Vical (U.S)
  14.2.5. ANI Pharmaceuticals, Inc. (U.S)
  14.2.6. and Genzyme Corporation (U.S)
  14.2.7. Novartis AG (Switzerland)
  14.2.8. Cell Medica (UK)

15. RESEARCH METHODOLOGY

16. KEY ASSUMPTIONS AND ACRONYMS